Accelerating the Global Deployment of Energy Storage Solutions via Battery Securitization Financing Program 19-08-2024, 20:10

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Cloudera Powers Autonomous Enterprise Agents for AI Practitioners with CrewAI 11-12-2024, 21:06